BDMD

Business Context and Reporting Period

Company: Baird Medical Investment Holdings Ltd (BDMD)
Reporting Period: Fiscal Year Ended December 31, 2025 (Annual Report on Form 20-F)
Business Overview: A Cayman Islands holding company operating primarily through PRC subsidiaries, specializing in the research, development, and sale of microwave ablation (MWA) medical devices for thyroid and other diseases. The company went public via a business combination with ExcelFin Acquisition Corp. in October 2024.

Key Financial Metrics (2025 vs. 2024)

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped 39.2% primarily due to a significant decrease in sales to direct customers (hospitals), which fell from $19.8 million in 2024 to $4.1 million in 2025. This was driven by lower sales volumes and prices for MWA needles and therapeutic apparatus.
• Expense Surge: Operating expenses more than doubled to $44.5 million.
  • R&D Expenses: Increased by 226% to $20.1 million, driven by FDA certification fees, CE Marking fees, and expenditures on AI ablation systems.
  • Selling & Marketing: Increased by 153% to $10.3 million, largely due to share-based compensation and staff costs.
  • G&A Expenses: Increased by 99% to $14.1 million, also driven by share-based compensation.
• Profitability Reversal: The company swung from a net income of $12.6 million in 2024 to a net loss of $27.5 million in 2025, resulting in a negative net margin of 122.2%.
• Liquidity Pressure: Cash and restricted cash decreased by $2.4 million to $0.57 million. Restricted cash of $0.39 million was held due to an unpaid administrative penalty from a 2021 manufacturing license lapse (paid in January 2026).

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management confirmed that controlling shareholders (Betters Medical and Haimei Wu) intend to provide financial support to ensure operations for at least 12 months. The company plans to fund future capital expenditures through existing cash, bank borrowings, and potential financing.
• Unusual Items:
  • Administrative Penalty: In November 2024, the company was penalized approximately $0.64 million (confiscation of revenue + fine) for a two-month gap in its manufacturing license in 2021. This resulted in restricted cash at year-end.
  • Stock-Based Compensation: A significant non-cash charge of $17.5 million was recorded in 2025 related to the 2024 Equity Incentive Plan.
• Key Risks:
  • Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding personnel knowledge of U.S. GAAP and lack of comprehensive accounting manuals. Remediation is ongoing.
  • Regulatory & Compliance: Risks related to PRC regulatory changes, including centralized procurement which could lower prices, and the requirement to upgrade Class II devices to Class III registration.
  • Customer Concentration: In 2025, the two largest customers accounted for 35.3% of total revenue.
  • HFCAA/Delisting: Risk of delisting if the PCAOB cannot inspect the company's auditor in China for two consecutive years.

Investor Verification Checklist

• Revenue Sustainability: Verify the reasons for the sharp 79% drop in direct hospital sales and whether distributor sales growth can offset this trend long-term.
• Cash Runway: Assess the sufficiency of the $0.57 million cash balance against the $27.5 million net loss and confirm the reliability of the controlling shareholders' commitment to provide additional working capital.
• Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting to avoid potential restatements or audit issues.
• Regulatory Pipeline: Track the status of Class III registration renewals and the impact of potential centralized procurement on pricing power.
• Share-Based Compensation: Evaluate the impact of recurring stock-based compensation expenses on future profitability.